InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.057 -0.006 (-9.52%)+
Announcement
Release
30 Apr 2026 9:01AM
Price at Release
$0.063
Full Release
download
Summary
Immutep Limited reported its quarterly activities for the period ending 31 March 2026. The company maintained a strong cash position, with approximately A$110.6 million in cash and term deposits, despite the discontinuation of its TACTI-004 Phase III trial. The cash flow report indicated net cash inflows from operating activities of A$13.5 million, with significant contributions from a US$20 million upfront payment from Dr. Reddy’s. However, the company anticipates a US$10 million payment to Dr. Reddy’s by June 2026, arising from the license agreement terms following the trial's discontinuation. Immutep has initiated cost reduction measures, including a reduction in headcount, to preserve capital. The company's cash runway is expected to extend into the first half of calendar year 2028. During the quarter, Immutep also reported progress in its various clinical trials, including the INSIGHT-003 Phase I trial and the EFTISARC-NEO Phase II trial, and received an orphan drug designation for eftilagimod alpha from the FDA.
Key Points
  • Immutep maintained strong cash reserves of A$110.6 million as of 31 March 2026.
  • TACTI-004 Phase III trial was discontinued, impacting cash flow.
  • Received a US$20 million upfront payment from Dr. Reddy’s.
  • Expected to pay US$10 million to Dr. Reddy’s by June 2026.
  • Cost reduction measures initiated to preserve capital.
  • Cash runway extends into the first half of 2028.
  • Progress in clinical trials including INSIGHT-003 and EFTISARC-NEO.
  • Received orphan drug designation for eftilagimod alpha from FDA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.